As the efficacy of HIPK2 expression as a prognostic and predictive factor for HPV-positive head and neck cancers is yet to be demonstrated, the present study was performed to address this clinically relevant question in tonsil cancers, stratified by HPV status and postoperative radiation therapy.
The primary antibodies were HIPK2 (1: 100; Abcam, Cambridge, UK) and p53 (1: 500; Novocastra, Newcastle, UK) and were incubated as previously described .
HIPK2 mRNA expression levels were measured using quantitative real-time RT-PCR by using TaqMan[R] Gene Expression Assays (Applied Biosystems Inc., Foster City, CA, USA; assay ID: HS00179759_m1 for HIPK2), as previously described .
Analyses of the correlations between the protein expression of HIPK2 and p53 and clinicopathological variables were carried out using the test or Fisher's exact test.
Increased HIPK2 Protein Expression and HIPK2 mRNA Expression Were Detected in Tonsil Cancers Compared to Normal Tonsillar Mucosa.
To elucidate the involvement of HIPK2 in tonsil cancer, we analyzed HIPK2 mRNA expression levels in 20 normal tonsil and 20 tonsil cancer FFPE samples.
Clinicopathological Correlations with HIPK2 Expression.
Prognostic Associations of HIPK2 Overexpression with HPV Infection and Postoperative Radiation Therapy.
We also investigated the prognostic differences associated with HIPK2 overexpression according to HPV status in patients with TSCC who received postoperative radiation therapy.
Multivariate analyses including HIPK2 overexpression, HPV infection, age, pT category, and contralateral nodal metastasis revealed that HIPK2 overexpression was an independent prognostic factor for DFS (P = 0.027, HR = 3.049, 95% CI: 1.133-8.206) in the radiation therapy group.
D'Orazi, "HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage," Oncogene, vol.
Schmitz, "A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress," Molecular Cell, vol.